


**AMENDMENTS TO THE CLAIMS**

1. (Previously presented) A quinuclidine derivative represented by Formula II




wherein

\_\_\_\_\_ represents an optional double bond;

n is 1, 2 or 3;

X represents a linker selected from -O-, -S-, -SO-, -SO<sub>2</sub>-, -CH<sub>2</sub>-, -C(=CH<sub>2</sub>)-, -NH-, -N(alkyl)-, -C(=O)-, -C(=S)-,



Y represents O, S, SO<sub>2</sub>, or NR', wherein R' represents hydrogen or alkyl.

2. (Original) The quinuclidine derivative of claim 1, wherein \_\_\_\_\_ represents a single (covalent) bond.

3. (Previously presented) The quinuclidine derivative of claim 1, wherein n is 1, 2 or 3.

4. (Previously presented) The quinuclidine derivative of claim 1, wherein X represents a linker selected from -O-, -S-, and -CH<sub>2</sub>-.
5. (Previously presented) The quinuclidine derivative of claim 1, wherein Y represents O, S, SO<sub>2</sub>, or NR', wherein R' represents hydrogen or alkyl.
6. (Original) The quinuclidine derivative of claim 5, which is  
(±)-3-(Dibenzofuran-2-yloxy)-1-azabicyclo[2.2.2]octane;  
or an enantiomer thereof, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof.
7. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a quinuclidine derivative of claim 1, or a pharmaceutically-acceptable addition salt thereof.

**8.-16. (Canceled)**

**17. (Canceled)**